Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Anemia 2Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Radiation Injuries 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma 1Esophageal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Breast Neoplasms 1

Interventions

pembrolizumab 18Nivolumab 7Carboplatin 7durvalumab 5Ipilimumab 5aldesleukin 4Paclitaxel 4Irinotecan 4Gemcitabine 4Docetaxel 4Cisplatin 4sargramostim 3atezolizumab 3Topotecan 3Polymerase Chain Reaction 3Magnetic Resonance Spectroscopy 3temsirolimus 2talazoparib 2carfilzomib 2cabozantinib 2budigalimab 2Trastuzumab 2Therapeutics 2Taxes 2Specimen Handling 2Psychiatric Rehabilitation 2Injections 2Gene Expression Profiling 2Fulvestrant 2Fluorodeoxyglucose F18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Epoetin Alfa × Gynecologic × Clear all
NCT00270166 2011-05-18

The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3 Completed
201 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryGynecologicLymphoidPlasma cellThoracic

Anemia, Breast Neoplasms, Esophageal Neoplasms, Lymphoma, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡